EGFR is an important driver of EMT, and our prior studies demonstrated that ST6Gal-I-mediated sialylation of EGFR promotes both basal and ligand-dependent EGFR activation in pancreatic and ovarian cancer cells (25). Here, ST6GAL1 is linked to ovarian carcinoma.